HLS Therapeutics Inc. (TSX:HLS)
Canada
· Delayed Price · Currency is CAD | Market Cap | 145.42M |
| Revenue (ttm) | 76.10M |
| Net Income (ttm) | -17.04M |
| Shares Out | 31.27M |
| EPS (ttm) | -0.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,500 |
| Average Volume | 6,253 |
| Open | 4.630 |
| Previous Close | 4.640 |
| Day's Range | 4.550 - 4.710 |
| 52-Week Range | 4.220 - 5.765 |
| Beta | 0.81 |
| RSI | 67.63 |
| Earnings Date | May 14, 2026 |
About HLS Therapeutics
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovas... [Read more]
Financial Performance
In 2025, HLS Therapeutics's revenue was $55.50 million, a decrease of -1.98% compared to the previous year's $56.62 million. Losses were -$12.43 million, -36.76% less than in 2024.
Financial numbers in USD Financial StatementsNews
HLS Therapeutics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
Operational improvements and a strengthened balance sheet have set the stage for accelerated growth, with new cardiovascular launches like Nilemdo and NEXLIZET targeting significant unmet needs. Early market access wins and a robust product pipeline support a positive outlook through 2027.
HLS Therapeutics Earnings Call Transcript: Q4 2025
Revenue and adjusted EBITDA grew in 2025, with strong Vascepa demand and a successful NILEMDO launch. Guidance for 2026 is conservative, with major growth expected in 2027 as public reimbursement expands and NEXLIZET launches.
HLS Therapeutics Earnings Call Transcript: Q3 2025
Adjusted EBITDA rose 19% in Q3 and 25% year-to-date, driven by operational improvements and cost discipline. Pasipa and Clozaril showed mixed performance, with strong growth in Western Canada and U.S. stability, while new cardiovascular launches are set to drive future growth.
HLS Therapeutics Earnings Call Transcript: Q2 2025
Q2 2025 saw revenue of $14.2M and adjusted EBITDA up 21%, with strong cash flow growth and reduced debt. Vascepa and Clozaril showed solid performance, and preparations for Nexletol/Nexlizet launch are on track, with minimal incremental costs expected.
HLS Therapeutics Transcript: AGM 2025
The meeting covered financial statements, director elections, and auditor reappointment, with all proposals passing. Virtual participation and voting were facilitated, and risk factors were highlighted. Voting results will be disclosed on SEDAR+ and via press release.
HLS Therapeutics Earnings Call Transcript: Q1 2025
Q1 2025 saw revenue and adjusted EBITDA growth, driven by strong Vascepa and Clozaril performance, operational efficiencies, and the in-licensing of Nexletol and Nexlizet. Guidance for 2025 remains unchanged, with no significant incremental spend expected for new product launches.
HLS Therapeutics Earnings Call Transcript: Q4 2024
2024 saw strong core product growth, major cost reductions, and significant debt repayment, positioning the company for 2025 EBITDA growth of 17–23%. Vascepa and Clozaril both contributed positively, with Vascepa expected to be profitable for the full year in 2025.
HLS Therapeutics Earnings Call Transcript: Q3 2024
Q3 saw strong Canadian growth for Vascepa and Clozaril, with operating expenses and debt significantly reduced. Vascepa is set to contribute positively to Adjusted EBITDA in Q4, while 2024 guidance was adjusted for U.S. Clozaril and FX impacts.
HLS Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024
Significant leadership and operational changes have refocused the business on its core product portfolio, driving growth in both psychiatric and cardiovascular markets. Financial performance is improving through cost reductions, debt repayment, and strong product demand, positioning the company for future expansion and profitability.
HLS Therapeutics Earnings Call Transcript: Q2 2024
Q2 saw 9% year-over-year growth in marketed product revenue, double-digit sales increases for Clozaril and Vascepa in Canada, and a 13% reduction in operating expenses. The Xenpozyme royalty sale enabled $14 million in debt repayment, strengthening the balance sheet.
HLS Therapeutics Transcript: AGM 2024
The meeting covered financial statements, elected eight directors, and reappointed the auditor, with all resolutions passing. Virtual procedures ensured shareholder participation, and risks related to forward-looking statements were highlighted.